Dr. Reddy's Laboratories acquires injectable product portfolio from Eton Pharma

24 Jun 2022 Evaluate

Dr. Reddy's Laboratories has acquired a portfolio of branded and generic injectable products from Deer Park, Illinois, based Eton Pharmaceuticals, Inc. (Eton Pharma). The portfolio includes the Biorphen (phenylephrine hydrocholoride) Injection and Rezipres (ephedrine hydrochloride) Injection NDAs with nine separate combinations of strengths and presentations and one first to-file approved ANDA for Cysteine Hydrochloride for the U.S. One strength each of Biorphen and Rezipres are currently commercially available in the U.S. The acquisition will complement Dr. Reddy's U.S. institutional business with limited competition injectable products.

Under the terms of the agreement, Dr. Reddy's acquired the Eton Pharma portfolio for an upfront payment of approximately $5 million in cash, plus contingent payments of up to $45 million. The acquisition supports Dr. Reddy's efforts to accelerate and expand affordable medications for patients.

Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.

Dr. Reddys Lab Share Price

1224.30 -15.70 (-1.27%)
28-Jan-2026 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1610.15
Dr. Reddys Lab 1224.30
Cipla 1331.80
Zydus Lifesciences 896.60
Lupin 2132.65
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×